EGFR and non-small cell lung carcinoma: Most importantly, the sensitivity to gefitinib and erlotinib dramatically increased in E-cadherin-overexpressing PC9/GR and H460/ER cells, respectively (Figure 4C), suggesting that E-cadherin repressed EMT in NSCLC cells, and subsequently enhanced the cytotoxic effect of EGFR-TKIs.